Reaction: Tenofovir disoproxil to 1 product

Reaction
Tenofovir disoproxil
DB00300
Tenofovir Monophosphate
DBMET01176
Reaction type
diester hydrolysis; phosphorylation
Direction
Not Available
Major circulating metabolite?
No
Spontaneous?
No
Activity
unknown
References
  1. Antoniou T, Park-Wyllie LY, Tseng AL: Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. Pharmacotherapy. 2003 Jan;23(1):29-43. [Article]
  2. Watkins ME, Wring S, Randolph R, Park S, Powell K, Lutz L, Nowakowski M, Ramabhadran R, Domanico PL: Development of a Novel Formulation That Improves Preclinical Bioavailability of Tenofovir Disoproxil Fumarate. J Pharm Sci. 2017 Mar;106(3):906-919. doi: 10.1016/j.xphs.2016.12.003. Epub 2016 Dec 14. [Article]
  3. Figueroa DB, Tillotson J, Li M, Piwowar-Manning E, Hendrix CW, Holtz TH, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant RM, Bumpus NN: Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067. PLoS One. 2018 Apr 11;13(4):e0195764. doi: 10.1371/journal.pone.0195764. eCollection 2018. [Article]
  4. Kearney BP, Flaherty JF, Shah J: Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595-612. doi: 10.2165/00003088-200443090-00003. [Article]
  5. Pruvost A, Negredo E, Benech H, Theodoro F, Puig J, Grau E, Garcia E, Molto J, Grassi J, Clotet B: Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2005 May;49(5):1907-14. doi: 10.1128/AAC.49.5.1907-1914.2005. [Article]
  6. Link [Link]
  7. Tenofovir FDA label [File]
Comments
Not Available
Enzymes
EnzymeKmVmaxRole
Adenylate kinase 2, mitochondrialNot AvailableNot Availableimplied
Adenylate kinase 4, mitochondrialNot AvailableNot Availableimplied